top of page

Presentations Given

Cardiologist in Amman Jordan
Cardiologist in Amman Jordan
Cardiologist in Amman Jordan
Cardiologist in Amman Jordan
Cardiologist in Amman Jordan

1. Prevalence of conventional cardiovasculr risk factors in Middle Eastern patients with coronary heart disease. The Jordan Hyperlipidemia and Related Targets Study (JoHARTS 2). The European Society of Cardiology Congress, Stockholm, September, 2005)

2. Is dyslipidemia among diabetics in the Middle East different from that in the West? 

The Jordan Hyperlipidemia and Related Targets Study (JoHARTS 3). The European Society of Cardiology Congress, Stockholm, September, 2005.

3. Survey of Jordanian physician's attitutde towards management of dyslipidemia in patients with cardiovascular disease. Presented at the 6th International Conference of Jordan Cardiac Society, Amman, October 2000.

4. Dyslipidemia in Jordanian patients with and without coronary heart disease: The Jordan and Related Targets Study (JoHARTS 1). The Emirates Heart Foundation Meeting, Amman. Jan 8, 2005.

5. Prevalence of conventional cardiovascular risk factors in Middle Eastern patients with coronary heart disease: The Jordan Hyperlipidemia and Related Targes Study (JoHARTS 2). The 3rd Middle East Africa ACS Workshop, Bahrain, April 7, 2005.

 

 

6. Prevalence of conventional cardiovascular risk factors in Middle Eastern patients with coronary heart disease: The Jordan Hyperlipidemia and Related Targes Study (JoHARTS 2). The World Hypertension League Meeting, Cairo, April 8, 2005.

7. Survey of Assessment and Management of Coronary Heart Disease Patients Analysis (SMART Study), Jordan data. First Middle East Africa Acute Coronary Syndrome Risks, Alexandria, Egypt, December 15, 2005

8. Low HDL-cholesterol in Jordan: Jordan Hyperlipidemia and Related Targets Study (JoHARTS-4). The First International Conference of the Jordan Atherosclerosis and Hypertension Society. March 21-23, 2006, Amman, Jordan.

9. The importance of managing lipid levels effectively in Middle Eastern/African patients. Lessons from the Jordan Hyperlipidemia and Related Targets Study (JoHARTS). Advances in the Management of CVD Workshop, Cairo, May 11-13, 2006.

10. The Jordanian ACS registries: SMART and MIDAS. The 2nd Middle Eastern/Africa ACS workshop. Cairo, February 15-16, 2006.

11. Jordan perspective on dyslipidemia and atherosclerosis: Lessons from large clinical studies. 2nd Middle East/Africa ACS Registry Workshop, February 2007, Cairo.

12. Jordan perspective on CAD and dyslipidemia in diabetics: Lessons from large clinical studies involving >11,000 individuals. The First Joint Jordanian American Endocrine Congress and Second Congress of the Jordanian Society of Endocrinology, Diabetes and Metabolism, Amman, May 2007.

13. Is high-sensitive C-Reactive Protein an independant predictor of future cardiovascular events in Middle Eastern patients with acute coronary syndrome? CRP and prognosis in acute coronary syndrome (CAPRIS) The Annual European Society of Cardiology Congress, Vienna, September, 2007.

14. Are there gender disparities in the treatment of Non-ST elevation and ST-elevation acute coronary syndromes in the Middle East? Observations from the SMART registry. The Annual European Society of Cardiology Congress, Vienna, September, 2007.

15. Adherence to acute coronary syndrome therapy guidelines in a large Middle Eastern population. Observations from the survey of management and assessment of coronary heart disease patients. The Annual European Society of Cardiology Congress, Vienna, September, 2007.

16. MINTOR study: AMI in Jordan. 4th ACS Workshop, Dubai, February 2008.

Publications

Cardiologist in Amman Jordan
Cardiologist in Amman Jordan
Cardiologist in Amman Jordan
Cardiologist in Amman Jordan
1. The JoHARTS investigators. Prevalence of conventional cardiovascular risk factors in Middle Eastern patients with coronary heart disease: The Jordan Hyperlipidemia and Related Targets Study (JoHARTS 2). International Journal of Cardiology 2006; 110:179-183
2. The JoHARTS investigators. Is dyslipidemia among diabetics in the Middle East different from that in the West? The Jordan Hyperlipidemia and Related Targets Study (JoHARTS 3). Clinical Diabetes Middle East 2006; 3:128-131
3. The JoHARTS investigators. Prevalence of conventional cardiovascular risk factors in Middle Eastern patients with coronary heart disease: The Jordan Hyperlipidemia and Related Targets Study (JoHARTS 2). European Heart Journal 2005, 26(suppl):45.
4. The JoHARTS investigators. Is dyslipidemia among diabetics in the Middle East different from that in the West? The Jordan Hyperlipidemia and Related Targets Study (JoHARTS 3). European Heart Journal 2005, 26 (suppl):495.
5. The JoHARTS investigators Dyslipidemia in 5000 Jordanians with or without coronary artery disease. The Jordan Hyperlipidemia and Related Targets Study (JoHARTS 3). Eastern Mediterranean Health Journal 2008.
6. The JoHARTS investigators. Prevalence of low levels of high-density lipoprotein cholesterol (HDL-C) among 5000 Jordanians: The Jordan Hyperlipidemia and Related Targets Study (JoHARTS-4). Pan Arab Medical Journal, in press 2008.
7. The CAPRIS investogators. Is high-sensitive C-Reactive Protein an independant predictor of future cardiovascular events in Middle Eastern patients with acute coronary syndrome? CRP and prognosis in acute coronary syndrome. European Heart Journal 2007; 28 (suppl): 595.
8. The CAPRIS investogators. Is high-sensitive C-Reactive Protein an independant predictor of future cardiovascular events in Middle Eastern patients with acute coronary syndrome? CRP and prognosis in acute coronary syndrome. International Journal of Atherosclerosis, in press.
9. The SMART registry investigators. Are there gender disparities in the treatment of Non-ST elevation and ST-elevation acute coronary syndromes in the Middle East? Observations from the SMART registry. European Heart Journal 2007; 28 (suppl): 94.
10. A. Hammoudeh, Y. Ismail, E. Al-Mousa. Adherence to acute coronary syndrome therapy guidelines in a large Middle Eastern Population. Observations from the survey of management and assessment of coronary heart disease patients (SMART survey). European Heart Journal 2007; 28 (suppl): 595.
11. The JCC group. Utilization of reperfusion therapy in the Myocardial Infarction Triggers and Onset in Jordan (MINTOR) Study. International Journal of Cardiology 2007; 122:156-157.
12. A. Hammoudeh, For the JoHARTS and JCC Groups. Prevalence of diabetes mellitus in large acute coronary syndrome studies in a Middle Eastern country: The road to "GLORY". Clinical Diabetes Middle East Medical Journal, in press.
13. A. Hammoudeh, for the JoHARTS Investigation group. The Jordan Hyperlipidemia and Related Targets Study (JoHARTS): Summary and Implications (part 1). Middle East Medical Journal, in press.
14. A. Hammoudeh, for the JoHARTS Investigation group. The Jordan Hyperlipidemia and Related Targets Study (JoHARTS): Summary and Implications (part 2). Middle East Medical Journal, in press.
15. A. Hammoudeh, for the JoHARTS Investigation group. The Jordan Hyperlipidemia and Related Targets Study (JoHARTS): Summary and Implications (part 3). Middle East Medical Journal, in press.
16. A. Hammoudeh, for the JoHarts Investigation group. The Jordan Hyperlipidemia and Related Targets Study (JoHARTS): Lessons and implications, a book in press.
Would like to learn more? 
bottom of page